Brief: Achieve Life Sciences Announces Last Subject Dosed In Phase 3 Orca-3 Trial Of Cytisinicline For Smoking Cessation
09/01/2023 13:29
Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES ANNOUNCES LAST SUBJECT DOSED IN
PHASE 3
ORCA-3 TRIAL OF CYTISINICLINE FOR SMOKING CESSATION
Source text for Eikon: ID:nGNX36DTWD
Further company coverage: ACHV.O
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock